stockrow
Friday 6 November 2026
Export TDOC’s income statement to Excel — free account
Teladoc Health, Inc.
TDOC Healthcare Health Information Services
Teladoc Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.5 billion, down 1.54% from fiscal 2024.
- Revenue
- −3.41%
- EPS
- +47.1%
- Free cash flow
- +11.8%
- Total debt
- +0.36%
Quarter to September 2026, against a year earlier
8.78
0.63
−6.70%
Follow TDOC
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.43 | 0.62 | 0.39 | 0.49 | |
P/FCF ratio |
8.36 | 17.33 | 7.71 | 8.98 | |
P/Operating CF |
9.91 | 23.74 | 102.59 | 14.06 | |
P/B ratio |
0.81 | 1.17 | 0.73 | 0.89 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.89 | 1.11 | 0.70 | 0.79 | |
EV/EBITDA |
10.23 | 13.51 | 9.38 | 10.79 | |
EV/Operating CF |
8.19 | 10.54 | 6.15 | 6.79 | |
EV/FCF |
17.43 | 31.09 | 13.99 | 14.55 | |
Quick Ratio |
0.76 | 0.72 | 2.38 | 2.41 | |
Current Ratio |
0.87 | 0.83 | 2.80 | 2.77 | |
Net Debt/EBITDA |
2.31 | 4.02 | 7.56 | 3.38 | |
Debt/Assets |
35.95% | 36.13% | 35.47% | 34.81% | |
Debt/Equity |
0.77 | 0.76 | 0.75 | 0.72 | |
Asset Turnover |
0.87 | 0.88 | 0.80 | 0.79 | |
Operating CF/Net income |
(3.95) | (1.66) | (0.15) | (3.49) | |
Capex/Depreciation |
(0.33) | (0.45) | (0.38) | (0.35) | |
Interest Coverage |
(5.69) | (7.26) | (11.51) | (7.27) | |
Research and Development Expense of Revenue |
10.83% | 10.36% | 11.06% | 11.15% | |
Selling, General and Administrative Expense of Revenue |
46.43% | 48.90% | 49.67% | 47.60% | |
Intangible Assets out of Total Assets |
0.50 | 0.53 | 0.54 | 0.55 | |
Share Based Compensation of Revenue |
1.92% | 1.53% | 2.38% | 2.48% | |
Graham Net Nets |
(0.24) | (0.20) | (0.35) | (0.29) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(14.79%) | (11.67%) | (17.80%) | (16.29%) | |
Free Cash Flow Yield |
11.96% | 5.77% | 12.98% | 11.13% | |
Revenue per Share |
3.33 | 3.35 | 3.43 | 3.64 | |
Operating CF per Share |
0.59 | 0.36 | 0.05 | 0.50 | |
Capex per Share |
(0.17) | (0.23) | (0.20) | (0.19) | |
Free Cash Flow per Share |
0.42 | 0.13 | (0.15) | 0.30 | |
Cash per Share |
4.67 | 4.28 | 4.19 | 4.43 | |
Shareholders Equity per Share |
7.12 | 7.24 | 7.46 | 7.86 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.12 | 7.24 | 7.46 | 7.86 | |
Free Cash Flow |
75.94 | 23.07 | (26.31) | 53.42 | |
Working Capital |
(189.49) | (233.37) | 727.47 | 714.39 | |
Capital Expenditures |
(30.52) | (41.59) | (35.82) | (34.32) | |
Net Current Asset Value |
(254.34) | (300.16) | (338.61) | (353.46) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.05 | 0.07 | 0.06 | 0.05 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
220.85 | 223.22 | 223.30 | 203.49 | |
Average Payables |
49.27 | 45.97 | 48.63 | 40.55 | |
Average Inventory |
35.33 | 33.49 | 34.78 | 38.17 | |
Average Assets |
2,826.81 | 2,826.31 | 3,125.85 | 3,187.41 | |
Average Common Equity |
1,343.42 | 1,366.12 | 1,381.67 | 1,438.39 |
Columns are period end dates · fundamentals updated 2 Nov 2026